Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease

Adv Chronic Kidney Dis. 2022 Mar;29(2):180-187.e1. doi: 10.1053/j.ackd.2022.03.005.

Abstract

Anemia is a common medical problem among patients with cancer and chronic kidney disease (CKD). Although anemia in patients with CKD is often treated with iron and erythropoietin-stimulating agents, there are controversies with regard to the use of erythropoietin-stimulating agents in cancer patients. In this article, we review the treatment of anemia in patients with cancer and CKD, in addition to summarizing the current guidelines in treatment of anemia in these patients.

Keywords: Anemia; CKD; Cancer; Dialysis; ESA; Iron.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anemia* / drug therapy
  • Anemia* / etiology
  • Erythropoietin* / therapeutic use
  • Hematinics* / therapeutic use
  • Humans
  • Kidney Failure, Chronic* / complications
  • Kidney Failure, Chronic* / therapy
  • Neoplasms* / complications
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / therapy

Substances

  • Hematinics
  • Erythropoietin